IN THE CLAIMS:

Claim 1. (Currently amended) A method for treating neoplasia in a mammal in need of such treatment, comprising treating said mammal with radiation therapy and a therapeutically effective amount of a matrix metalloproteinase inhibitor or a pharmaceutically-acceptable salt ~~thereof~~ of a matrix metalloproteinase inhibitor.

Claim 2. (Original) The method of claim 1 wherein the neoplasia is selected from the group consisting of lung cancer, breast cancer, gastrointestinal cancer, bladder cancer, head and neck cancer and cervical cancer.

Claim 3. (Currently amended) A method for treating neoplasia in a subject in need of such treatment, comprising treating said mammal with radiation therapy and a therapeutically effective amount of a matrix metalloproteinase inhibitor or a pharmaceutically-acceptable salt of a matrix metalloproteinase inhibitor ~~thereof~~, wherein the matrix metalloproteinase inhibitor is selected from compounds~~, and their pharmaceutically acceptable salts thereof~~, of the group consisting of:

1)



N-hydroxy-1-(4-methylphenyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

2)



1-cyclopropyl-N-hydroxy-4-[[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

3)



N-hydroxy-1-(phenylmethyl)-4-[[4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

4)



N-hydroxy-1-(4-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride;

5)



N-hydroxy-2,3-dimethoxy-6-[[4-[4-(trifluoromethyl)phenoxy]-1-piperidinyl]sulfonyl]benzamide;

6)



N-hydroxy-1-(4-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride;

7)



N-hydroxy-1-(3-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride;

8)



N-hydroxy-1-(2-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

9)



~~British Biotech BB-2516 (Marimastat),~~ N4-[2,2-dimethyl-1-[(methylamino)carbonyl]propyl]- N-1,2 -dihydroxy-3 (2-methylpropyl)-, [2S-[N4(R*),2R*,3S*]]-);

10)



~~Bayer Ag Bay-12-9566,~~ 4-[(4'-chloro[1,1'-iphenyl]-4-yl)oxy]-2-[(phenylthio)methyl]butanoic acid;

11)



~~Agouron Pharmaceuticals AG-3340,~~ N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide;

12) ~~CollaGenex Pharmaceuticals CMT-3 (Metastat),~~ 6-demethyl-6-deoxy-4-dedimethylaminotetracycline;

13) ~~Chiroscience D-2163,~~ 2-[1S-([(2R,S)-acetylmercapto-5-phthalimido]pentanoyl-L-leucyl)amino-3-methylbutyl]imidazole;

14)



N-hydroxy-4-[[4-(phenylthio)phenyl]sulfonyl]-1-(2-propynyl)-4-piperidinecarboxamide monohydrochloride;

15)



N-hydroxy-1-(2-methoxyethyl)-4-[[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

16)



N-hydroxy-1-(2-methoxyethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinearboxamide;

17)



1-cyclopropyl-N-hydroxy-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

18)



4-[[4-(cyclohexylthio)phenyl]sulfonyl]-N-hydroxy-1-(2-propynyl)-4-piperidinecarboxamide monohydrochloride;

19)



4-[[4-(4-chlorophenoxy)phenyl]sulfonyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide;

20)



N-hydroxy-4-[[4-(4-methoxyphenoxy)phenyl)sulfonyl]-1-(2-propynyl)-4-piperidinecarboxamide;

21)



1-cyclopropyl-4-[[4-[(4-fluorophenyl)thio]phenyl]sulfonyl]-N-hydroxy-4-piperidinecarboxamide;

22)



1-cyclopropyl-N-hydroxy-4-[[4-(phenylthio)phenyl]sulfonyl]-4-piperidinecarboxamide;

23)



tetrahydro-N-hydroxy-4-[[4-(4-pyridinylthio)phenyl]sulfonyl]-2H-pyran-4-carboxamide;

24)



tetrahydro-N-hydroxy-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-2H-pyran-4-carboxamide.

Claim 4 (Currently amended). A method for treating neoplasia in a mammal in need of such treatment, comprising treating said mammal with radiation therapy and a therapeutically effective amount of a matrix metalloproteinase inhibitor or a pharmaceutically-acceptable salt of a matrix metalloproteinase inhibitor ~~thereof~~, wherein the matrix metalloproteinase inhibitor is selected from compounds~~, and their pharmaceutically acceptable salts thereof,~~ of the group consisting of:

1)



N-hydroxy-1-(4-methylphenyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

2)



1-cyclopropyl-N-hydroxy-4-[[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

3)



N-hydroxy-1-(phenylmethyl)-4-[[4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

4)



N-hydroxy-1-(4-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride;

5)



N-hydroxy-2,3-dimethoxy-6-[[4-[4-(trifluoromethyl)phenoxy]-1-piperidinyl]sulfonyl]benzamide;

6)



N-hydroxy-1-(4-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride;

7)



N-hydroxy-1-(3-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride;

8)



N-hydroxy-1-(2-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

9)



~~British Biotech BB-2516 (Marimastat),~~ N-4-[2,2-dimethyl-1-[(methylamino)carbonyl]propyl]-N-1,2-dihydroxy-3(2-methylpropyl)-, [2S-[N4(R*),2R*,3S*]]-);

10)



~~Bayer Ag Bay-12-9566,~~ 4-[(4'-chloro[1,1'-iphenyl]-4-yl)oxy]-2-[(phenylthio)methyl]butanoic acid;

11)



~~Agouron Pharmaceuticals AG-3340,~~ N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide;

12) ~~CollaGenex Pharmaceuticals CMT-3 (Metastat),~~ 6-demethyl-6-deoxy-4-dedimethylaminotetracycline; and

13) ~~Chiroscience D-2163,~~ 2- [1S-([(2R,S)-acetylmercapto-5-phthalimido]pentanoyl-L-leucyl)amino-3-methylbutyl]imidazole.

Claim 5. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is



N-hydroxy-1-(4-methylphenyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride.

Claim 6. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is



1-cyclopropyl-N-hydroxy-4-[[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride.

Claim7. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is



N-hydroxy-1-(phenylmethyl)-4-[[4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride.

Claim 8. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is



N-hydroxy-1-(4-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride.

Claim 9. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is



N-hydroxy-2,3-dimethoxy-6-[[4-[4-(trifluoromethyl)phenoxy]-1-piperidinyl]sulfonyl]benzamide.

Claim 10. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is



N-hydroxy-1-(4-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride.

Claim 11. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is



N-hydroxy-1-(3-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride.

Claim 12. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is



N-hydroxy-1-(2-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride.

Claim 13. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is



British Biotech BB-2516 (Marimastat), N4-[2,2-dimethyl-1-[(methylamino)carbonyl]propyl]-N1,2-dihydroxy-3(2-methylpropyl)-, [2S-[N4(R*),2R*,3S*]]-).

Claim 14. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is



Bayer Ag Bay-12-9566,4-[(4'-chloro[1,1'- iphenyl]-4-yl)oxy]-2-[(phenylthio)methyl]butanoic acid.

Claim 15. (Currently amended) The method of claim 3 wherein the matrix metalloproteinase inhibitor is



~~Agouron Pharmaceuticals AG-3340,~~ N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide.

Claim 16. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is CollaGenex Pharmaceuticals CMT-3 (Metastat), 6-demethyl-6-deoxy-4-dedimethylaminotetracycline.

Claim 17. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is Chiroscience D-2163, 2-[1S-([(2R,S)- acetylmercapto-5-phthalimido]pentanoyl-L-leucyl)amino-3-methylbutyl]imidazole.

Claim 18. (Canceled)

Claim 19. (Original) The method of Claim 1 wherein the combination is administered in a sequential manner.

Claim 20. (Original) The method of Claim 1 wherein the combination is administered in a substantially simultaneous manner.

Claim 21. (Original) The method of Claim 3 wherein the combination is administered in a sequential manner.

Claim 22. (Original) The method of Claim 3 wherein the combination is administered in a substantially simultaneous manner.